Advertisement

Organisation › Details
Abivax S.A. (Euronext Paris: ABVX)
ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral drugs and human therapies to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months. ABX464 has been developed using ABIVAX’ anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients’ clear important pathogenic viruses. Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy. ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation. The company is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). *
![]() |
Start | 2013-12-27 restructured |
Group | Abivax (Group) | |
![]() |
Industry | therapeutic vaccine |
Industry 2 | virostatic agent | |
![]() |
Person | Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD) |
Person 2 | Kenny, Daniel (Abivax 201410– COO + VP Business Development before Baxter Vaccines + Baxter BioScience) | |
![]() |
Region | Paris |
Country | France | |
Street | 5 rue de la Baume | |
City | 75008 Paris | |
Tel | +33-1-5383-0841 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2023-06-30) |
Currency | EUR | |
Annual sales | 4,583,000 (income, operating, total (2022) 2022-12-31) | |
Profit | -60,740,000 (2022-12-31) | |
Cash | 26,950,000 (2022-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-04-03 |
Advertisement

More documents for Abivax (Group)
- [1] Abivax S.A.. (10/24/23). "Press Release: Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market". Paris....
- [2] Abivax S.A.. (10/20/23). "Press Release: Abivax Announces the Pricing of Its Initial Public Offering on the Nasdaq Global Market". Paris....
- [3] Abivax S.A.. (9/29/23). "Press Release: Abivax Files Registration Statement for Proposed Initial Public Offering in the United States". Paris....
- [4] Abivax S.A.. (8/23/23). "Press Release: Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations". Paris....
- [5] Abivax S.A.. (8/21/23). "Press Release: Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions". Paris....
- [6] Abivax S.A.. (7/11/23). "Press Release: Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors". Paris....
- [7] Abivax S.A.. (9/2/22). "Press Release: Abivax Announces Successful Oversubscribed EUR 49.2M Cross-over Financing with Top-tier US and European Biotech Investors [not for US]". Paris....
- [8] Abivax S.A.. (7/23/21). "Press Release: Abivax Announces the Pricing of Its Oversubscribed Capital Increase of EUR 60M and Convertible Bonds of EUR 25M, Totaling EUR 85M New Financing". Paris....
- [9] Abivax S.A.. (6/23/21). "Press Release: Abivax Reports Excellent Phase 2a Clinical Safety and Efficacy Results with 50mg ABX464 in Rheumatoid Arthritis". Paris....
- [10] Abivax S.A.. (3/14/19). "Press Release: Abivax 2018 Financial Results and Operations Update". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top